Your browser is no longer supported. Please, upgrade your browser.
Settings
KITE Kite Pharma, Inc. daily Stock Chart
KITE [NASD]
Kite Pharma, Inc.
Index- P/E- EPS (ttm)-6.91 Insider Own1.70% Shs Outstand57.35M Perf Week0.12%
Market Cap10.26B Forward P/E- EPS next Y-7.03 Insider Trans-34.80% Shs Float53.22M Perf Month41.94%
Income-359.10M PEG- EPS next Q-2.14 Inst Own90.50% Short Float10.22% Perf Quarter100.35%
Sales32.10M P/S319.61 EPS this Y-134.30% Inst Trans1.00% Short Ratio2.68 Perf Half Y110.61%
Book/sh12.52 P/B14.29 EPS next Y14.60% ROA-48.90% Target Price146.22 Perf Year210.41%
Cash/sh13.62 P/C13.13 EPS next 5Y- ROE-59.60% 52W Range39.82 - 179.69 Perf YTD298.95%
Dividend- P/FCF- EPS past 5Y- ROI-63.20% 52W High-0.11% Beta-
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low350.78% ATR3.01
Employees447 Current Ratio9.00 Sales Q/Q110.40% Oper. Margin- RSI (14)88.96 Volatility0.30% 1.48%
OptionableYes Debt/Eq0.00 EPS Q/Q-48.20% Profit Margin- Rel Volume0.89 Prev Close178.89
ShortableYes LT Debt/Eq0.00 EarningsAug 08 BMO Payout- Avg Volume2.03M Price179.50
Recom2.80 SMA206.75% SMA5033.12% SMA200109.29% Volume1,795,995 Change0.34%
Aug-29-17Upgrade Wedbush Underperform → Neutral $180
Aug-29-17Downgrade Guggenheim Buy → Neutral
Aug-29-17Downgrade Canaccord Genuity Buy → Hold $120 → $180
Aug-28-17Downgrade SunTrust Buy → Hold
Aug-28-17Downgrade BTIG Research Buy → Neutral
Jul-13-17Downgrade Maxim Group Buy → Hold
Jul-10-17Reiterated Jefferies Buy $101 → $121
May-09-17Reiterated FBR & Co. Outperform $90 → $91
May-09-17Downgrade Wedbush Neutral → Underperform $60 → $54
May-08-17Downgrade Raymond James Outperform → Mkt Perform
Mar-13-17Downgrade Standpoint Research Buy → Hold
Mar-06-17Reiterated RBC Capital Mkts Outperform $85 → $95
Mar-03-17Downgrade Stifel Buy → Hold $74
Mar-02-17Downgrade Citigroup Buy → Neutral
Mar-01-17Reiterated Maxim Group Buy $77 → $84
Feb-28-17Reiterated H.C. Wainwright Buy $78 → $85
Feb-22-17Initiated Wells Fargo Market Perform
Feb-02-17Initiated Wedbush Neutral $46
Jan-04-17Initiated ROTH Capital Buy $68
Nov-21-16Initiated H.C. Wainwright Buy $78
Sep-19-17 07:09AM  Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade InvestorPlace
06:09AM  Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors Motley Fool
Sep-18-17 03:07PM  Why Bellicum Pharmaceuticals Stock Is Rising Today Motley Fool
11:35AM  Gilead Sciences: Is The Kite Deal Too Little, Too Late? Barrons.com
10:30AM  3 Value Stocks for Smart Investors Motley Fool
Sep-15-17 02:21PM  AbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share Investor's Business Daily
11:07AM  After Gilead Sciences, More Biotech M&A? Barrons.com
07:45AM  3 Reasons Why Gilead Sciences Stock Is a Buy Now Motley Fool
Sep-14-17 11:44AM  Gilead Sciences, Inc. -- Moody's assigns A3 to Gilead's new sr. notes; stable outlook Moody's
Sep-13-17 07:39PM  3 Biotech Stocks That Have Already Quadrupled in 2017 Motley Fool
03:05PM  Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals) Motley Fool
10:12AM  Gilead: Too Early for Kite Credit? Barrons.com
07:37AM  Must-Know Recent Developments for Gilead Market Realist
Sep-11-17 04:02PM  5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition Motley Fool
02:20PM  The Move in SPDR S&P Biotech (ETF) (XBI) ETF Is Coming Get on Board InvestorPlace
08:55AM  Implied Volatility Surging for Kite Pharma (KITE) Stock Options Zacks
08:03AM  See what the IHS Markit Score report has to say about Kite Pharma Inc. Markit
Sep-10-17 05:00AM  CAR-T Mania: Could Juno Therapeutics Get Acquired Next? Motley Fool
Sep-07-17 06:28PM  Myth Busting: Trump Trade A Fallacy Forbes
05:15PM  Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus Zacks
05:10PM  Are These Healthcare Stocks Top Takeover Targets? Motley Fool
02:54PM  Are You Buying Gilead Sciences, Inc. for the Wrong Reason? Motley Fool
08:11AM  Alternative Perspectives On The Biotech M&A Environment Forbes
07:00AM  This years best-performing ETF could rise even higher CNBC
06:04AM  5 Things Gilead Sciences' Management Just Said That You'll Want to Know Motley Fool
Sep-06-17 05:08PM  Have Investors Already Priced In Kite Pharma Incs (KITE) Growth? Simply Wall St.
02:20PM  Why Kite Pharma Soared 64.8% in August Motley Fool
Sep-05-17 03:58PM  6 ETF Picks for September Zacks
11:26AM  Why It's Useful To Know A Company's Competitors When Trading Benzinga
08:53AM  Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better Motley Fool
08:00AM  Biotech Stocks Back in Favor: Will the Rally Continue? Zacks
07:15AM  Why Juno Therapeutics Shares Vaulted 46% Higher in August Motley Fool
Sep-03-17 07:02AM  Why Gilead Sciences Shares Soared 10.6% in August Motley Fool
Sep-02-17 10:33AM  3 Biotech Stocks That Skyrocketed This Week Motley Fool
10:20AM  Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition TheStreet.com
Sep-01-17 11:40PM  [$$] Charting the Market Barrons.com
08:27PM  3 Reasons Gilead Sciences Jumped to Buy Kite Pharma Motley Fool
05:12PM  Gilead Sciences Oncology M&A Strategy Explained Motley Fool
04:13PM  Wonder Why Gilead Sciences Bought Kite Pharma? Heres the Answer! Motley Fool
12:48PM  Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods Zacks
11:29AM  4 Biotech Stocks That More Than Doubled This Year Zacks
10:49AM  Biotech ETFs Remain Bell of the Ball ETF Trends
10:09AM  5 Top Performing Stocks of the Top ETF of August Zacks
12:30AM  [$$] Hopeful News of the Week The Wall Street Journal
Aug-31-17 09:00PM  Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences Motley Fool
07:15PM  [$$] Hopeful News of the Week The Wall Street Journal
07:09PM  ETFs with exposure to Kite Pharma, Inc. : August 31, 2017 Capital Cube
06:23PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE PR Newswire
04:37PM  A Sign Of Things To Come? Traders Are Betting On More Biotech Mergers Benzinga
03:25PM  Could Gilead Sciences Stock Skyrocket 25%? 1 Analyst Thinks So Motley Fool
02:14PM  Novartis CAR-T gene therapy, the first approved by FDA, to cost $475,000 MarketWatch
10:55AM  Gilead Sciences: No, the Novartis Approval Wasn't Good News Barrons.com
09:08AM  Incyte and Gilead Sciences: S&P 500s Top Gainers on August 30 Market Realist
08:42AM  Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update Zacks
Aug-30-17 07:01PM  Cramer: There Should Be More Takeovers Where These Came From TheStreet.com
06:46PM  Cramer pinpoints the trend that could lead to a surge in ... CNBC Videos
06:33PM  Cramer: This trend could lead to surge in takeovers CNBC Videos
06:32PM  Cramer pinpoints the trend that could lead to a surge in takeovers CNBC
04:57PM  Why Analog Devices, Gilead Sciences, and Universal Display Jumped Today Motley Fool
03:10PM  Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap Zacks
02:58PM  After Gilead's Acquisition Of KITE, Who Gets Gobbled Up Next? Forbes
01:59PM  Novartis: A New $475,000 Drug Barrons.com
01:35PM  The Way We Treat Cancer Will Be Revolutionized As Gene Therapy Comes to the U.S. Fortune
01:25PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Kite Pharma, Inc. to Gilead Sciences, Inc. is Fair to Shareholders Business Wire
12:38PM  Novartis Wins FDA Approval for CAR-T; So Why Is Gilead Getting a Boost? Barrons.com
11:11AM  [$$] Gilead Overpays; Next Takeout Targets Barrons.com
11:07AM  A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved Business Insider
10:44AM  Cool Your Hopes for a Post-Kite Cancer-Deal Boom Bloomberg
10:01AM  Gilead-Kite: A New Transformative Deal For Biotech Forbes
08:49AM  Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal Zacks
08:48AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG Zacks
08:04AM  Has Gilead Sciences' Big Bounce Begun With the Kite Pharma Buyout? Motley Fool
07:00AM  Featured Company News - Gilead Sciences Announces Acquisition of Kite Pharma; Plans to Establish its Position in the Cell Therapy Sector for Cancer Treatment ACCESSWIRE
Aug-29-17 06:46PM  Harwood Feffer LLP Announces Investigation of Kite Pharma, Inc. PR Newswire
04:51PM  Gilead to Fly High with Kite Pharma Acquisition for $11.9B Zacks
04:12PM  Analysts Mixed On Gilead-Kite, But One Key Rival Stands To Benefit Investor's Business Daily
03:52PM  Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition Zacks
01:50PM  Why Juno Therapeutics Stock Is Blasting Off Today Motley Fool
01:43PM  Gilead: Hardly a Surprise, Hardly a Triumph, Hardly Transformative? Barrons.com
12:44PM  Biotech ETFs Soar on Gilead-Kite Deal Zacks
12:07PM  Analysts Weigh In On Gilead-Kite Pharma Deal Benzinga
11:26AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Kite Pharma, Inc. to Gilead Sciences, Inc. is Fair to Shareholders Business Wire
10:38AM  Company News For August 29, 2017 Zacks
10:34AM  Can Gilead Sciences Squeeze $12 Billion From Kite Pharma? Motley Fool
09:56AM  WALL STREET PAYDAY: Banks could reap $90 million in fees from the Gilead-Kite deal Business Insider
09:56AM  Juno Therapeutics Stock Climbs, Wedbush Sees Advantages from Gilead, Kite Deal TheStreet.com
09:40AM  3 Biotechnology Stocks Heating Up On Acquisition News ACCESSWIRE
08:12AM  What Can A Company Justifiably Charge For A Cancer Cure? Forbes
07:15AM  Here's What Else Gilead Sciences Gets by Buying Kite Pharma Motley Fool
07:04AM  Get Ready for More Acquisitions by Gilead Sciences Motley Fool
06:19AM  [$$] US pharma Gilead faces pricing dilemma with new cancer treatment Financial Times
12:10AM  [$$] Gilead Has Earned the Benefit of the Doubt The Wall Street Journal
12:08AM  [$$] Gilead Bets $11 Billion on New Cancer Therapy The Wall Street Journal
12:01AM  Asian stocks fall, rattled by North Korean missile launch Associated Press
Aug-28-17 11:14PM  Here's why Gilead broke its dealmaking hiatus and splurged $12 billion on a cancer treatment Business Insider +28.00%
09:36PM  SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Kite Pharma, Inc. - KITE ACCESSWIRE
08:05PM  [$$] Gilead Bets $11 Billion on New Cancer Therapy The Wall Street Journal
07:15PM  PRESS DIGEST- Financial Times - Aug 29 Reuters
06:36PM  Cramer: Why Apple matters more to the market than Hurrica... CNBC Videos
06:23PM  Cramer: Why this stock matters more to the market than Hu... CNBC Videos
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptor (CAR)-based therapy that is in Phase 2 clinical trials for patients with relapsed or refractory aggressive diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma. The company is also conducting a Phase 2 clinical trial of KTE-C19 on patients with relapsed/refractory mantle cell lymphoma; a Phase 1-2 clinical trial of KTE-C19 on adult patients with relapsed/refractory acute lymphoblastic leukemia; and a Phase 1-2 clinical trial of KTE-C19 in pediatric patients with relapsed/refractory, as well as Phase 1b/2 clinical trial of KTE-C19 in combination with Genentech's atezolizumab in patients with refractory DLBCL. In addition, it engages in developing T cell receptors-based therapies, which targets self-antigens, viral antigens, and neo-antigens. The company has a research collaboration and license agreement with Amgen Inc. to develop and commercialize various CAR-based product candidates; cooperative research and development agreements with the U.S. Department of Health and Human Services; a license agreement with Cabaret Biotech Ltd. and National Institutes of Health; a license and research agreement with Alpine Immune Sciences, Inc.; and a research collaboration and license agreement with Cell Design Labs, Inc. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BUTITTA CYNTHIA MChief Operating OfficerAug 10Option Exercise1.3515,00020,250132,795Aug 14 05:03 PM
Kim Helen SusanEVP, Business DevelopmentAug 10Option Exercise52.856,251330,36924,915Aug 14 05:04 PM
Kim Helen SusanEVP, Business DevelopmentAug 10Sale120.096,251750,68318,664Aug 14 05:04 PM
BUTITTA CYNTHIA MChief Operating OfficerAug 10Sale120.7215,0001,810,758117,795Aug 14 05:03 PM
Kim Helen SusanEVP, Business DevelopmentAug 08Option Exercise53.9079,9494,309,25198,613Aug 10 04:57 PM
Kim Helen SusanEVP, Business DevelopmentAug 08Sale119.5679,9499,558,32418,664Aug 10 04:57 PM
MOORE TIMOTHY L.EVP, Technical OperationsAug 03Option Exercise44.916,000269,46055,400Aug 04 07:50 PM
MOORE TIMOTHY L.EVP, Technical OperationsAug 03Sale110.066,000660,34349,400Aug 04 07:50 PM
MOORE TIMOTHY L.EVP, Technical OperationsAug 01Option Exercise44.913,000134,73061,400Aug 03 09:14 PM
MOORE TIMOTHY L.EVP, Technical OperationsAug 01Sale107.6912,0001,292,32249,400Aug 03 09:14 PM
Kim Helen SusanEVP, Business DevelopmentJul 31Option Exercise52.9626,6491,411,43745,313Aug 01 07:00 PM
Kim Helen SusanEVP, Business DevelopmentJul 31Sale109.2826,6492,912,27218,664Aug 01 07:00 PM
BUTITTA CYNTHIA MChief Operating OfficerJul 10Option Exercise1.3515,00020,250132,795Jul 11 05:36 PM
BUTITTA CYNTHIA MChief Operating OfficerJul 10Sale103.0915,0001,546,300117,795Jul 11 05:36 PM
Wiezorek JeffreySVP Clinical DevelopmentJul 03Option Exercise6.8910,00068,90031,071Jul 06 06:15 PM
Wiezorek JeffreySVP Clinical DevelopmentJul 03Sale104.3210,0001,043,20121,071Jul 06 06:15 PM
WITTE OWEN N.DirectorJun 26Sale100.6012,5001,257,50076,250Jun 26 07:55 PM
WITTE OWEN N.DirectorJun 23Option Exercise18.0012,500225,000101,250Jun 26 07:55 PM
WITTE OWEN N.DirectorJun 23Sale100.0012,5001,250,00088,750Jun 26 07:55 PM
BUTITTA CYNTHIA MChief Operating OfficerJun 23Sale100.815,000504,033112,795Jun 27 12:25 PM
CHAMPSI FARAHDirectorJun 16Sale88.115,450480,2000Jun 16 05:41 PM
Ruchefsky Steven BDirectorJun 14Sale89.4820,0001,789,574205,426Jun 16 05:43 PM
CHAMPSI FARAHDirectorJun 14Sale90.4015,0001,356,00063,664Jun 16 05:41 PM
BUTITTA CYNTHIA MChief Operating OfficerJun 09Option Exercise1.3510,00013,500127,795Jun 12 07:16 PM
BUTITTA CYNTHIA MChief Operating OfficerJun 09Sale88.5510,000885,491117,795Jun 12 07:16 PM
DOUMANI ROYDirectorJun 08Sale84.535,000422,634150,017Jun 09 09:11 PM
DOUMANI ROYDirectorJun 07Sale84.4610,000844,621155,017Jun 09 09:11 PM
Kim Helen SusanEVP, Business DevelopmentJun 01Option Exercise51.432,400123,43221,064Jun 05 05:05 PM
Kim Helen SusanEVP, Business DevelopmentJun 01Sale72.452,400173,88018,664Jun 05 05:05 PM
JENKINSON PAUL LChief Financial OfficerMay 10Buy72.593,000217,7703,000May 10 03:12 PM
JENKINSON PAUL LChief Financial OfficerMay 10Buy72.5745032,6577,480May 10 03:12 PM
Ruchefsky Steven BDirectorMay 09Buy69.501,40097,300225,426May 10 12:52 PM
BONDERMAN DAVIDDirectorMay 09Buy68.9450,0003,446,9982,408,084May 09 06:29 PM
Nussbaum RanDirectorMay 09Buy69.119,832679,4743,520May 11 02:02 PM
Belldegrun ArieChairman, President and CEOMay 09Buy68.5717,0001,165,69085,507May 09 03:37 PM
Chang David DEVP, R&D, Chief Medical Off.May 01Option Exercise6.8920,000137,80070,165May 03 06:06 PM
Kim Helen SusanEVP, Business DevelopmentMay 01Option Exercise53.902,400129,36021,064May 03 06:08 PM
Kim Helen SusanEVP, Business DevelopmentMay 01Sale82.122,400197,08818,664May 03 06:08 PM
Chang David DEVP, R&D, Chief Medical Off.May 01Sale82.0920,0001,641,74450,165May 03 06:06 PM
CHAMPSI FARAHDirectorApr 28Sale82.592,617216,1384,962May 01 06:52 PM
CHAMPSI FARAHDirectorApr 27Sale82.7716,5511,369,9267,579May 01 06:52 PM
CHAMPSI FARAHDirectorApr 26Sale82.7251,3124,244,59724,130Apr 26 05:38 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 25Option Exercise1.3515,00020,250132,795Apr 27 06:49 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 25Sale81.8515,0001,227,690117,795Apr 27 06:49 PM
CHAMPSI FARAHDirectorApr 25Sale82.8046,7833,873,58575,442Apr 26 05:38 PM
CHAMPSI FARAHDirectorApr 24Sale82.3425,8182,125,854122,225Apr 26 05:38 PM
CHAMPSI FARAHDirectorApr 17Sale82.4843,1013,555,028148,043Apr 17 09:24 PM
CHAMPSI FARAHDirectorApr 13Sale82.3972,2755,954,737191,144Apr 17 09:24 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 03Option Exercise1.355,0006,750122,795Apr 04 04:15 PM
Kim Helen SusanEVP, Business DevelopmentApr 03Option Exercise53.902,400129,36021,064Apr 04 04:16 PM
Chang David DEVP, R&D, Chief Medical Off.Apr 03Option Exercise6.8920,000137,80070,165Apr 04 04:17 PM
Chang David DEVP, R&D, Chief Medical Off.Apr 03Sale81.5420,0001,630,86650,165Apr 04 04:17 PM
Kim Helen SusanEVP, Business DevelopmentApr 03Sale81.802,400196,32018,664Apr 04 04:16 PM
BUTITTA CYNTHIA MChief Operating OfficerApr 03Sale81.965,000409,798117,795Apr 04 04:15 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 27Option Exercise1.3510,00013,500127,795Mar 28 07:57 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 27Sale77.6710,000776,746117,795Mar 28 07:57 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 09Option Exercise1.3521,11828,509138,913Mar 10 05:25 PM
BUTITTA CYNTHIA MChief Operating OfficerMar 09Sale80.7821,1181,705,929117,795Mar 10 05:25 PM
Kim Helen SusanEVP, Business DevelopmentMar 01Option Exercise53.902,400129,36021,064Mar 02 06:05 AM
DOUMANI ROYDirectorMar 01Option Exercise1.3550,00067,50075,065Mar 02 06:06 AM
Wiezorek JeffreySVP Clinical DevelopmentMar 01Option Exercise6.8918,000124,02039,071Mar 02 06:09 AM
BUTITTA CYNTHIA MChief Operating OfficerMar 01Option Exercise1.3528,88238,991146,677Mar 01 09:59 PM
Chang David DEVP, R&D, Chief Medical Off.Mar 01Option Exercise6.8960,000413,400110,165Mar 02 06:08 AM
BUTITTA CYNTHIA MChief Operating OfficerMar 01Sale80.0528,8822,312,004117,795Mar 01 09:59 PM
Kim Helen SusanEVP, Business DevelopmentMar 01Sale75.432,400181,03918,664Mar 02 06:05 AM
Wiezorek JeffreySVP Clinical DevelopmentMar 01Sale75.0118,0001,350,14421,071Mar 02 06:09 AM
DOUMANI ROYDirectorMar 01Sale76.772,800214,94225,065Mar 02 06:06 AM
DOUMANI ROYDirectorMar 01Sale74.0516,0001,184,873115,017Mar 02 06:06 AM
Chang David DEVP, R&D, Chief Medical Off.Mar 01Sale79.1660,0004,749,44150,165Mar 02 06:08 AM
Kim Helen SusanEVP, Business DevelopmentFeb 28Option Exercise52.2747,9002,503,75666,564Mar 02 06:05 AM
Kim Helen SusanEVP, Business DevelopmentFeb 28Sale67.4047,9003,228,37218,664Mar 02 06:05 AM
BUTITTA CYNTHIA MChief Operating OfficerFeb 27Option Exercise1.3510,00013,500127,795Mar 01 09:59 PM
BUTITTA CYNTHIA MChief Operating OfficerFeb 27Sale54.4210,000544,178117,795Mar 01 09:59 PM
Wiezorek JeffreySVP Clinical DevelopmentFeb 01Option Exercise6.891,50010,33522,195Feb 06 04:36 PM
Wiezorek JeffreySVP Clinical DevelopmentFeb 01Sale51.211,50076,82020,695Feb 06 04:36 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 31Option Exercise1.3510,00013,500127,795Feb 01 07:09 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 31Sale50.5610,000505,562117,795Feb 01 07:09 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 06Option Exercise1.3510,00013,500127,795Jan 10 05:03 PM
Wiezorek JeffreySVP Clinical DevelopmentJan 06Option Exercise6.891,50010,33522,195Jan 10 05:04 PM
Wiezorek JeffreySVP Clinical DevelopmentJan 06Sale50.001,50075,00020,695Jan 10 05:04 PM
BUTITTA CYNTHIA MChief Operating OfficerJan 06Sale50.1310,000501,289117,795Jan 10 05:03 PM
Wiezorek JeffreySVP Clinical DevelopmentDec 20Sale50.8671636,41615,095Dec 22 04:53 PM
Tomasello ShawnChief Commercial OfficerDec 20Sale50.864,901249,26549,635Dec 22 04:52 PM
Kim Helen SusanEVP, Business DevelopmentDec 20Sale50.8693647,6058,064Dec 22 04:51 PM
Chang David DEVP, R&D, Chief Medical Off.Dec 20Sale50.861,78890,93825,123Dec 22 04:50 PM
Belldegrun ArieChairman, President and CEODec 20Sale50.863,493177,65424,707Dec 22 04:47 PM
BUTITTA CYNTHIA MChief Operating OfficerDec 20Sale50.862,482126,23592,995Dec 22 04:48 PM
Wiezorek JeffreySVP Clinical DevelopmentDec 01Option Exercise6.891,50010,33517,311Dec 05 07:03 PM
Wiezorek JeffreySVP Clinical DevelopmentDec 01Sale50.761,50076,13415,811Dec 05 07:03 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 25Option Exercise1.3510,00013,500105,477Nov 29 05:02 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 25Sale50.4010,000504,01595,477Nov 29 05:02 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 10Option Exercise1.3510,00013,500105,477Nov 14 06:57 PM
Wiezorek JeffreySVP Clinical DevelopmentNov 10Option Exercise6.891,50010,33517,311Nov 14 06:55 PM
BUTITTA CYNTHIA MChief Operating OfficerNov 10Sale50.6510,000506,46795,477Nov 14 06:57 PM
Wiezorek JeffreySVP Clinical DevelopmentNov 10Sale50.181,50075,27015,811Nov 14 06:55 PM
Wiezorek JeffreySVP Clinical DevelopmentOct 03Option Exercise6.891,50010,33517,311Oct 05 07:44 PM
Wiezorek JeffreySVP Clinical DevelopmentOct 03Sale54.811,50082,21415,811Oct 05 07:44 PM
BUTITTA CYNTHIA MChief Operating OfficerSep 26Option Exercise1.3510,00013,500105,477Sep 28 05:03 PM
BUTITTA CYNTHIA MChief Operating OfficerSep 26Sale54.1310,000541,30095,477Sep 28 05:03 PM